Clinical Implications of Genomic Discoveries in Lung Cancer
N Engl J Med 2016; 374:1864-1873May 12, 2016DOI: 10.1056/NEJMra1504688
Many genetic lesions have been identified in lung cancers. The findings shed light on molecular pathogenesis and have led to the definition of abnormalities that can be targeted by therapeutic agents that occasionally elicit dramatic responses.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
We thank Siddhartha Devarakonda, M.D., and Subramanian Venkatesan, Ph.D., for their assistance with the figures and David Ornitz, Ph.D., for his helpful suggestions.
From the Translational Cancer Therapeutics Laboratory, Francis Crick Institute, and the Cancer Research UK (CRUK) Lung Cancer Centre of Excellence, University College London Hospitals and Cancer Institute, London (C.S.); and the Division of Oncology, Department of Medicine, and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis (R.G.).
Address reprint requests to Dr. Govindan at the Division of Oncology, Washington University School of Medicine, 660 S. Euclid, Box 8056, St. Louis, MO 63110, or email@example.com.
No hay comentarios:
Publicar un comentario